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Abstract
Background: Renal transplantation is the best treatment for kidney failure, in terms of length and quality of life and
cost-effectiveness. However, most transplants fail after 10 to 12 years, consigning patients back onto dialysis.
Damage by the immune system accounts for approximately 50% of failing transplants and it is possible to identify
patients at risk by screening for the presence of antibodies against human leukocyte antigens. However, it is not
clear how best to treat patients with antibodies. This trial will test a combined screening and treatment protocol in
renal transplant recipients.
Methods/Design: Recipients >1 year post-transplantation, aged 18 to 70 with an estimated glomerular filtration
rate >30 mL/min will be randomly allocated to blinded or unblinded screening arms, before being screened for the
presence of antibodies. In the unblinded arm, test results will be revealed. Those with antibodies will have
biomarker-led care, consisting of a change in their anti-rejection drugs to prednisone, tacrolimus and mycophenolate
mofetil. In the blinded arm, screening results will be double blinded and all recruits will remain on current therapy
(standard care). In both arms, those without antibodies will be retested every 8 months for 3 years. The primary
outcome is the 3-year kidney failure rate for the antibody-positive recruits, as measured by initiation of long-term
dialysis or re-transplantation, predicted to be approximately 20% in the standard care group but <10% in
biomarker-led care. The secondary outcomes include the rate of transplant dysfunction, incidence of infection, cancer
and diabetes mellitus, an analysis of adherence with medication and a health economic analysis of the combined
screening and treatment protocol. Blood samples will be collected and stored every 4 months and will form the basis
of separately funded studies to identify new biomarkers associated with the outcomes.
Discussion: We have evidence that the biomarker-led care regime will be effective at preventing graft dysfunction
and expect this to feed through to graft survival. This trial will confirm the benefit of routine screening and lead to a
greater understanding of how to keep kidney transplants working longer.
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Background
The problem addressed by this study is premature trans-
plant failure – kidney transplants do not last for the nat-
ural lifespan of most recipients. Premature in this context
refers to the lifespan of the recipienta. Current death-
censored 10-year transplant survival rates vary between
59% and 70%, so 30% to 40% of patients have their trans-
plant for <10 years [1]. Since 2000, a consistent annual at-
trition rate of around 3% of kidney transplants [2] means
that approximately 700 patients return to dialysis each
year in the United Kingdom. Although many of these pa-
tients are eligible for a second transplant, the legacy of the
first often makes it harder to find a well-matched second
kidney. In addition, second (and any subsequent) trans-
plants have a shorter lifespan than the original trans-
plant, so the problem of premature failure becomes
amplified. Of the various reasons why transplanted kid-
neys fail, the single most common cause is immune-
mediated injury [3].
Two types of study have linked antibodies (Ab) against
human leukocyte antigen (HLAs) to immune-mediated
injury and premature graft failure. Case–control studies
have compared patients who have lost grafts with those
in whom grafts are still working, performing retrospect-
ive analysis of prospectively collected serum samples.
For instance, Mizutani et al. [4] studied 39 patients with
failed grafts due to chronic rejection (CR) and 26 matched
controls with functioning grafts. In the former group, 72%
had immunoglobulin G (IgG) HLA Ab, compared to 46%
of controls. Similar results were obtained from a different
study of a separate population [5]. The surprising thing
from these studies was the high incidence of HLA Ab in
patients with working grafts. There are several potential
explanations for this. It is possible that factors relating to
the HLA Ab (such as complement fixing ability) or factors
in addition to the Ab, influence the progression of CR and
thus the timing of eventual graft rejection. A second, re-
lated possibility, is that all patients with HLA Ab develop
pathology, but it progresses at different rates, such that
patients showing up in the control groups in these studies
are deteriorating more slowly. Evidence for this comes
from Mizutani et al. [4], who showed that their CR group
with HLA Ab showed progressive deterioration of renal
function prior to graft failure. The same progressive
deterioration was seen in the control group of patients
with HLA Ab, whose grafts did not fail. These data illus-
trate that CR is a time-dependent process in which pro-
gressive graft dysfunction precedes graft failure. Moreover,
the time from development of HLA Ab to graft failure is
highly variable in different people.
Separate studies have reported the prospective follow-
up of outcomes in those with HLA Ab. Terasaki and
Ozawa [6] studied 2,231 patients. In a group of 479 with
HLA Ab, the 2-year graft failure rate was 15%, compared
to 6.8% in the 1,753 with no HLA Ab. This trial noted
that the patients who failed within 2 years had worse
renal function on testing than those that did not, con-
sistent with the fact that CR is a progressive and time-
dependent process and those that fail are at the end of
this process. In another study, the same group [7] re-
ported that the 4-year survival rate for 1,329 patients, all
with functioning transplants, was 58% for those with
HLA Ab (158 patients) vs 81% for those without (806).
Lachmann et al. [8] performed the best study to date.
The study was based at a single centre in Berlin and had
1,014 patients with stable kidney function (for the 6
months pre-recruitment) and were on average 6 years
post-transplantation. Patients were tested for HLA Ab
and prospectively followed for 5½ years. Grafts failed in
37% of the 302 who had HLA Ab, but in only 17% of the
712 patients who tested negative for HLA Ab. Moreover,
in this latter group, a subgroup of 195 patients had a
repeat test performed 2½ years into the study. Of these,
148 remained negative and only 6% of grafts failed in
this group. In contrast, 47 had developed new HLA Ab
since the beginning of the study and 21% of these suf-
fered graft failure, confirming that the development of
new HLA Ab in the negative group was predictive of fu-
ture graft loss. Finally, this study identified a difference
between the prognostic value of HLA Ab that were spe-
cific for the donor, known as donor-specific antibodies
(DSA), which were found in 33% of HLA Ab + patients,
and those that were not (non-DSA), found in 66%. Graft
failure rates were 51% over 5.5 years in patients with
DSA and 30% in patients with non-DSA. In a subgroup
of patients who had transplant biopsies, 78% of those
with failed grafts and HLA Ab + had changes consistent
with CR. They concluded that grafts in patients with
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HLA Ab were more than three times likely to fail than
those without, even when corrected for age, sex, year of
transplant, estimated glomerular filtration rate (GFR)
and number of previous kidney transplants. These find-
ings have been corroborated by a second study from the
Netherlands [9], in which the risk of graft failure with
HLA Ab was also shown to be independent of graft
dysfunction and proteinuria.
Therefore, the literature indicates that HLA Ab are a
prognostic biomarker and could be used as a screening
test to identify patients at high risk of premature kidney
transplant failure. All transplant units in the United
Kingdom have the ability to detect HLA Ab, but routine
systematic post-transplant screening of patients has not
been generally adopted because it is not clear how best
to treat patients once identified. Although there is a wide-
spread view in the literature that HLA Ab cause CR, there
is no evidence of this in humans. The chief investigator’s
group has been investigating patients with CR for several
years and has evidence that the activity of T and B cells is
most strongly associated with progression of CR and that
this subgroup benefits from enhanced immunosuppres-
sion (Shiu et al., manuscript in preparation). This study
will therefore test a combined screening and treatment
protocol for HLA Ab in a randomised controlled trial.
Methods/Design
Trial objectives
Primary objective
The primary objective is the 3-year graft failure rate for
patients testing positive for HLA Ab at baseline or within
3 years of randomisation who receive an optimised anti-
rejection medication intervention with prednisone, tacroli-
mus (tac) and mycophenolate mofetil (MMF) (treatment),
compared to a control group who test positive for HLA
Ab at baseline or within 3 years post-randomisation who
remain on their established immunotherapy and whose
clinicians are not aware of their Ab status.
Secondary objectives
Determine the 3-year graft failure rate in patients rando-
mised to unblinded HLA Ab screening, compared to a
control group randomised to blinded HLA Ab screening.
Determine whether the treatment influences patient
survival.
Determine whether the treatment influences the devel-
opment of graft dysfunction as assessed by the presence of
proteinuria (protein/creatinine ratio (PCR) > 50) or a
change in the estimated glomerular filtration rate (eGFR).
Determine whether the treatment influences the rate
of acute rejection for these groups.
Determine the adverse effect profiles of treatment in
this group, in particular whether they are associated with
increased risk of infection, malignancy or diabetes melli-
tus (DM).
Determine the cost-effectiveness of routine screening
for HLA Ab and prolonging transplant survival using
this screening and treatment protocol.
Determine the impact of biomarker screening and the
treatment on the patients’ adherence to drug therapy
and their perceptions of the risk to the health of the
transplant.
Collect regular samples from patients enrolled in the
HLA Ab + groups to enable an in-depth scientific ana-
lysis of the HLA Ab and cells of the immune and repair
systems and to develop more sophisticated biomarkers
for progression and/or responsiveness to therapy (to be
funded separately, not as part of the efficacy and mech-
anism evaluation (EME) programme).
Primary end points
The primary end point is the 3-year graft failure rate in
HLA Ab + patients. Graft failure will be defined as restart-
ing long-term dialysis or requiring a new transplant. Time
zero starts at the time of randomisation, once the result of
the HLA test is known. For those patients who are HLA
Ab– at randomisation but become Ab + during a subse-
quent screening, time zero will be reset at the time of the
positive test, and the follow-up time will be extended to
allow for the 3-year end point.
Secondary end points
The secondary clinical end points are:
 3-year graft failure rates in all patients recruited to
the trial
 Patient survival
 Rate of progression of graft dysfunction, as assessed
by the change in the degree of proteinuria (PCR >
50) or the change in estimated GFR over 3 years
 Rate of biopsy-proven rejection over 3 years
 Rates of culture- or polymerase chain reaction-
positive infection, biopsy-proven malignancy and DM
 Health economic analysis of outcomes
 Analysis of adherence and perceptions of risk for the
biomarker-led care (BLC) groups
 The secondary scientific end points are:
 Changes in characteristics of HLA Ab and
laboratory parameters of T and B cell phenotypes
and responsiveness for the HLA Ab + groups
 Change in numbers and phenotype of circulating
CD34+ cells for the HLA Ab + groups
Trial design
This is a prospective open-labelled randomised marker-
based strategy trial, with a standard control, where
biomarker stratification is based on HLA Ab status. The
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biomarker-strategy design is appropriate for testing the
clinical utility of a biomarker [10]. Recruitment will take
place in five British renal transplant units over 3 years,
with recruits followed for at least 3 years. The trial de-
sign is shown in the flow diagram in Figure 1, which
shows the number of patients anticipated to be in each
group by the end of the trial, based on sample size cal-
culations, consent rates, eligibility and estimated attri-
tion. Recipients of cross-match negative transplants aged
18 to 70, >1 year post-transplant with eGFR ≥ 30 will be
asked to give consent for the screening/treatment process.
The first stratification will be based on blood test
screening for HLA Ab. Approximately 30% will be HLA
positive, with approximately 70% negative. HLA Ab + pa-
tients will be further screened with single-antigen beads
(SAB) to determine whether DSA are present (approxi-
mately will have 1/3 DSA and 2/3 non-DSA). Thus, bio-
marker stratification has three arms (DSA+, non-DSA +
and HLA Ab–). The second stratification will be based on
current immunosuppression to ensure balanced numbers
already on tac or MMF in each group. The immunosup-
pression stratification has four groups: MMF only, tac
only, both tac and MMF, and neither tac nor MMF. The
third stratification factor will be the recruiting study site
(five sites).
HLA Ab + patients will be randomised 1:1 into either
blinded standard care (SC) or unblinded BLC. Patients
in the former (groups A1 and A2 in Figure 1) will be
blind to their biomarker status and will remain on base-
line immunotherapy, whereas the clinicians of patients
in the latter (groups B1 and B2 in Figure 1) will know
their HLA Ab status and will be offered treatment. HLA
Ab– patients will remain on their existing immunother-
apy and randomised 1:1 into either the blinded (C) or
unblinded group (D), with only the latter knowing their
HLA Ab status. Both these groups will receive regular
Ab status monitoring for the first 3 years. Those patients
who become positive during subsequent screening rounds
Figure 1 OuTSMART flow diagram. *Randomisation is performed using the results of a recruit’s first screening test. Those with donor specific
antibodies (DSA) undergo no further screening as part of the trial (but serum will be stored for analysis of human leukocyte antigen antibody
profiles later). †Those initially HLA Ab– undergo routine screening every 8 months. There is no second randomisation. A recruit allocated to
blinded standard care (group C) who becomes HLA Ab + (black lines) will remain in a standard care group (group A1 or A2). If in the unblinded
standard care group (D), they will change to unblinded biomarker-led treatment care (group B1 or B2) (orange lines). ‡ The numbers in each
group are those anticipated at the primary end point. Ab, antibodies; DSA, donor-specific antibodies; HLA, human leukocyte antigen; MMF,
mycophenolate mofetil; tac, tacrolimus.
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(approximately 10% per year) will be moved to the appro-
priate HLA Ab + groups (DSA + or non-DSA+) for final
data analysis. All patients in group D found to be positive
on the second or subsequent rounds will be offered the
same treatment as those patients who were positive in the
first screening round, and followed up for 3 additional
years from the time they become positive. Thus, the max-
imum amount of time any single patient can remain in
the study is 6 years. ‘New’ patients, randomised but ini-
tially HLA negative at baseline, will be included in the
intended primary analysis of HLA positive groups at each
successive 8 monthly screening round. The patient flow
diagram according to CONSORT guidelines is provided as
Figure 2.
Sample size calculations
The primary purpose of this trial is to demonstrate super-
ior outcomes using a defined treatment strategy compared
to standard care for biomarker (HLA Ab) positive patients.
Once superiority is demonstrated for HLA Ab + patients, it
is also necessary to demonstrate non-inferior outcomes
when comparing the unblinded screening strategy to the
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blinded standard of care for the entire patient population,
including those HLA Ab–. The graft failure rate 3 years
after screening has been chosen as a clinically relevant pri-
mary outcome. As a reference for power calculations, we
have used the observed failure rates reported by Lachmann
et al. [8] for HLA Ab + and HLA Ab– patients. Since fail-
ure rates differ between DSA + and non-DSA + patients,
sample size calculations have been carried out separately
for these groups. Following these calculations, we esti-
mated the number to be screened, based on expected
dropout rates, expected screening results and eligibility cri-
teria (see below). We based our estimates of the differences
in primary outcome between the groups on, first, the re-
sults of our preliminary data from patients with CR treated
with a similar regime as used here, and second, our assess-
ment that large differences in primary outcome will be
needed to make the screening programme cost-effective.
Hypothesis testing will be sequential [11]. Superiority
will be tested first in the HLA Ab + groups to demon-
strate the efficacy of the treatment. If this analysis is
significant, then non-inferiority will be tested for the
entire population to demonstrate the clinical utility of
the biomarker screening. We calculated the sample size
needed to show the superiority of the treatment opti-
misation for biomarker-positive patients using the hy-
potheses as follows.
Hypothesis 1.1: HLA Ab + patients with DSA, rando-
mised to standard care (A1) will show higher graft failure
rates than patients randomised to biomarker-led care (B1).
We hypothesise that the experimental treatment will
bring the failure rate of group B1 down to that of non-
DSA patients in standard care (A2). Assuming a 30%
failure rate for group A1 (as in [8]), and a 16% failure
rate for group B1, 139 patients per group will provide
80% power and 5% type I errors, for a two-sided test.
Hypothesis 1.2: HLA Ab + patients, with non-DSA, ran-
domised to standard care (A2) will show higher graft failure
rate than patients randomised to biomarker-led care (B2).
We hypothesise that the experimental treatment will
bring the failure rate of group B2 down to that of bio-
marker negative patients in standard care (C). Assuming
a 16% failure rate for group A2 (as in [8]), and a 6%
failure rate for group B2, 146 patients per group will
provide 80% power and 5% type I errors, for a two-sided
test.
The numbers enrolled in groups A and B include
those patients initially enrolled in groups C or D who
become HLA Ab + during re-screening.
We calculated the sample size needed to show the
non-inferiority of all unblinded patients compared to all
blinded patients as follows.
Hypothesis 2: All patients randomised to unblinded
screening (combined groups B1 + B2 + D) will show equal
or lower graft failure rates than all patients randomised
to blinded screening (combined groups A1 + A2 + C), irre-
spective of biomarker status.
At the end of the trial, we expect 60% of patients to be
in the HLA Ab– groups, 13% in DSA + groups and 27%
in non-DSA + groups (after dropouts). Assuming a 6%
failure rate in biomarker negative groups C and D, the
estimated average failure rate of all blinded screening
patients is 11.8% (that is, (6 × 0.6) + (16 × 0.27) + (30 ×
0.13)). Similarly, the estimated average failure rate in the
unblinded screening group is 7.3%. We have established
a non-inferiority limit of 5% absolute difference, so that
the unblinded group would be considered non-inferior
with a failure rate of 16.8% or lower. For this purpose,
1,043 patients in each arm would provide 90% power
and 2.5% (one-sided) type I errors.
We will keep recruiting until every group has acquired
the number required to test both hypotheses. When
calculating the number of patients to screen for eligibil-
ity and to recruit, the following assumptions were made:
(1) 60% of patients under follow-up at each transplant
centre will meet the eligibility criteria, (2) 10% will refuse
consent, (3) the prevalence of HLA Ab in most trans-
plant populations is 25% to 30%, (4) 6% of initially Ab–
patients will become Ab + in each screening round and
(5) 2% will drop out every screening round.
Based on these assumptions and a recruitment audit
in participating centres, we have estimated that we need
to assess eligibility for 4,672 patients and enrol 2,522 to
ensure sufficient numbers are in each group at the pri-
mary end point to test both hypotheses. Figure 1 shows
the number of patients needed in each of the arms to
reach the primary end point to test hypothesis 2, which
is sufficient to test hypotheses 1.1 and 1.2 (the numbers
in groups A and B include those patients initially enrolled
in groups C or D who were found to be HLA Ab + during
re-screening).
A recruitment audit has revealed that there is a very
high chance of recruiting all the required patients from
five participating centres within 3 years. We anticipate
recruiting sufficient numbers of patients to all groups by
screening round 3 or 4. Each centre is expected to re-
cruit similar numbers of patients.
Statistical analysis
Primary analysis
Statistical analysis will be on an intention-to-treat and
treatment-received basis. We will consider the patients
who become positive during the follow-up in the appro-
priate group.
The proportion of graft failures for each of the groups
is denoted by πA1, πB1, etc.
Superiority (hypothesis 1):
H0: πA1 = πB1 and πA2 = πB2
H1: πA1 ≠ πB1 and πA2 ≠ πB2
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To test superiority for the primary outcome for the bio-
marker (HLA Ab) positive groups (hypotheses 1.1 and
1.2), we will use a two-sided Z-test at the 5% level of sig-
nificance, and will calculate the 95% CI for the difference
in the proportion of graft failures between the biomarker-
led care and standard care groups. The biomarker-led care
groups will be considered superior if the absolute Z > 1.96,
and our assumptions with respect to the size of the differ-
ences will supported if the CI includes a positive differ-
ence in proportions of 14% for hypothesis 1.1, and 10% for
hypothesis 1.2.
Non-inferiority (hypothesis 2):
H0: πUnblind – πBlind ≥ δ
H1: πUnblind – πBlind < δ
To test for non-inferiority of the unblinded groups
compared to the blinded groups (hypothesis 2), we will
carry out a one-sided Z-test at the 2.5% level of signifi-
cance. We will conclude non-inferiority if H0 is rejected,
and the corresponding upper bound of the 95% CI ex-
cludes the limit δ (set at 5% more failures in the un-
blinded groups).
Secondary analysis
A similar procedure will be followed for secondary binary
outcomes. We will use Cox proportional hazards regres-
sion to analyse survival outcomes. For continuous second-
ary outcomes we will use a two-sample t-test, transforming
data where they are skewed.
Exploratory moderator analysis
Additionally, for all primary and secondary analyses, we
will carry out multivariable analyses, using generalised
linear models, to adjust for the effects of stratification
factors (for example, the previous immunosuppression
regime). In this case, we will use the corresponding odds
ratio to evaluate the adjusted size of the differences be-
tween proportions, by transforming back the estimated
odds ratio associated with the treatment group into
absolute differences in proportions. If the results of the
analysis of the primary outcome are significantly affected,
the adjusted effects will be taken as final.
Handling missing data
Where a given outcome is measured at two or more time
points, missing post-randomisation assessments will be
dealt with by fitting linear mixed models to all the avail-
able measures using maximum likelihood methods. Such
an approach provides valid inferences under the assump-
tion that the missing data mechanism is ignorable (or
Missing at Random). If post-randomisation variables are
found to be predictive of the dropout rate, multiple imput-
ation will be considered using K-nearest neighbours.
Economic evaluation
Cost data is usually skew but will be analysed using arith-
metic means so that total costs are preserved. Non-
normality in errors will be allowed for by using generalised
linear models with an appropriate error structure (for
example, a gamma distribution [12]). Incremental cost-
effectiveness ratios or an incremental cost-utility ratio will
be presented where appropriate. Cost-effectiveness accept-
ability curves will be plotted to summarise the uncertainty
in cost-effectiveness.
Detailed study plan
Selection of subjects
The local transplant clinic database will be used to identify
patients meeting the baseline inclusion and exclusion
criteria. At the start of the trial, the entire population of
transplant clinic attendees who meet the eligibility criteria
are potentially eligible for recruitment. On subsequent
screening rounds, patients who reach 12 months post-
transplantation after the start of the trial will become
eligible and these will be recruited before the next screen-
ing round.
Informed consent
Potentially eligible patients will be approached at a rou-
tine clinic appointment by the principal investigator (PI)
or research nurses and given printed and verbal informa-
tion about the trial. They will have the opportunity to
return for a second consultation within a few days to
give informed consent for recruitment into the study or
to do this on their next routine appointment. Alterna-
tively, eligible patients will be sent information about the
study through the post, for discussion and consent at
their next routine appointment. Following consent, full
eligibility criteria will be reviewed. This may include test-
ing for chronic viral diseases (if they have not been tested
within the last 5 years) and pregnancy (if a patient’s history
suggests there is the possibility of pregnancy).
Inclusion criteria
 Sufficient grasp of English language to give written
and witnessed informed consent to participate
 Renal transplant recipients >1 year post-
transplantation, male or female
 Aged 18 to 70 years
 Estimated glomerular filtration rate (eGFR) ≥ 30,
based on the four-variable Modification of Diet in
Renal Disease (MDRD) approach
Exclusion criteria
 Recipient requiring HLA desensitisation to remove
antibodies for a positive cross-match transplant
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 Recipient known already to have HLA antibodies
who has received specific intervention for those
antibodies or for CR
 Recipient of an additional solid organ transplant (for
example, pancreas, heart, etc.)
 History of malignancy in previous 5 years (excluding
non-melanomatous tumours limited to the skin)
 Positive for hepatitis B surface antigens, hepatitis B
core antibodies, hepatitis C or HIV (according to a
test performed within the previous 5 years)
 History of acute rejection requiring escalation of
immunosuppression in the 6 months prior to
screening
 Patient enrolled in any other study involving
administration of another investigational medical
product (IMP) at time of recruitment
The following exclusion criteria are based on the sum-
maries of the product characteristics of the IMPs:
 History of an ongoing or previous infection (no
time limit) that would prevent optimisation of
immunosuppression, including ocular herpes
simplex
 Known hypersensitivity to any of the IMPs
 Known hereditary disorders of carbohydrate
metabolism
 Pregnancy or breastfeeding females (based on verbal
history of recipient)
 Pre-menopausal females who refuse to consent to
using suitable methods of contraception throughout
the trial
Randomisation procedure and code break
Prior to randomisation but after consent, site staff will
register a recruit on the web-based electronic data cap-
ture system (InferMed MACRO), hosted at the King’s
Clinical Trials Unit (KCTU). Each will be assigned a
unique study patient identification number (PIN) by the
system. Samples from all recruits will be sent to the
HLA laboratory, along with this PIN and a sample re-
quest form containing other information required for
randomisation.
Laboratory staff will screen for HLA Ab and perform
SAB testing on positive screening samples to check for
the presence of DSA. Once this information is known,
the lab staff will access the KCTU randomisation system
and randomise the patient, using the HLA Ab results.
Randomisation will be further stratified by centre and
current immunosuppression. The lab staff, PIs and
nurses at the site will be automatically emailed and the
randomisation system will inform them whether the pa-
tient is in a blinded or unblinded group. If the patient is
in an unblinded group, the system will inform the PI of
the HLA Ab status. Unblinded patients will be identified
by blue stickers appended to the notes and all future
clinical samples. The system will tell the trial staff to
enter HLA Ab– patients into the subsequent 8-monthly
screening rounds, and also whether the patients have
been selected to provide future samples for the 4-
monthly scientific analysis (for transfer to the chief in-
vestigator’s laboratory). This information will be relayed
using a star on the blue labels that are appended to the
laboratory request forms.
The notes and samples from blinded patients will have
green stickers and labels. The HLA Ab status will not be
given to the PIs or trial staff. A star will be used to tell
the trial staff which recruits have been selected to pro-
vide 4-monthly samples for transfer back to the chief
investigator’s lab for scientific analysis. These patients
will have samples taken every 8 months for HLA Ab
screening. Once inside the lab, the lab staff will use their
knowledge of the HLA status to determine which HLA
Ab– patients will undergo screening. The samples from
HLA Ab + patients will be discarded.
On the second and subsequent HLA Ab screening
rounds, the lab staff will update the randomisation sys-
tem. The results from patients in the unblinded groups
only will be forwarded to the PI and laboratory staff via
email. This will indicate whether the status has changed,
which will trigger the change in the treatment protocol
for those that have changed from HLA Ab negative to
positive.
Laboratory staff at each recruiting site, with access to
HLA Ab results, will be provided with a unique user-
name and password to access the randomisation system.
Password access must be authorised by the trial manager
in all cases and direct requests from sites will not be
processed. Access to the system is via the internet [13]
by clicking the ‘randomisation – advanced’ link and select-
ing the OuTSMART Trial.
There are no blinded study medications in the trial so
no emergency code break is required. In the event that a
study site clinician wishes to be made aware of blinded
laboratory results, this must be discussed and agreed
with the trial manager and the chief investigator in all
cases. It is not anticipated that unblinding in this man-
ner will be required and only in extraordinary circum-
stances would this be agreed.
Trial medication
All treatments will be introduced on the basis that they
will be tailored to the individual patient, according to
compliance, tolerance and achievement of target levels
(for tac). Failure to tolerate one or more of the compo-
nents of the protocol (or refusal to take any of the
agents) will not be used as a reason for withdrawal from
the study.
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Investigational medical products and dosing regimen
The optimised treatment protocol in the two groups (B1
and B2 in Figure 1) with HLA Ab will be:
 Mycophenolate mofetil twice, three times or four
times per day, or enteric-coated mycophenolic acid
twice per day, with the daily dose determined ac-
cording to local unit guidelines. The patient will be
stabilised on the maximum tolerated dose.
 Tacrolimus once or twice per day, according to local
unit preference, with dose titrated to achieve 12-
hour post-dose levels of 4 μg/L to 8 μg/L (4 ng/mL
to 8 ng/mL). The patient will be stabilised on the
maximum tolerated dose that achieves these levels.
 Prednisolone once per day. Starting at 20 mg for
two weeks, then reducing by 5 mg once per day
every two weeks down to their previous
maintenance dose or 5 mg once per day.
After consultation with the Medicines and Healthcare
products Regulatory Agency (MHRA), we have confirmed
that all these medicines will be classed as IMPs, whereas
all others will not. Mycophenolate mofetil/mycophenolic
acid is being used outside of its marketing authorisation
(which states that it should be used with ciclosporin).
However, because it is now used widely in combination
with tacrolimus in most units in the UK, the two can be
regarded as standard care. We therefore propose that
the three drugs will not require labelling in line with
annex 13 of the Rules Governing Medicinal Products in
the European Union. This means the IMPs can be man-
aged as normal, through a general practitioner or hos-
pital prescription (as appropriate) and will not require
special labelling, accountability, storage, etc.
Concomitant medication
Patients in all groups will have blood pressure controlled
and total cholesterol lowered, using agents according to
local unit guidelines and working to unit-defined targets.
All other medication and treatment will be determined
by local unit guidelines.
Withdrawal of subjects
Individual recruits can withdraw at any time for any rea-
son. Failure to tolerate one or more components of the
treatment will definitely not be seen as a reason to with-
draw an individual participant from the trial but is to be
anticipated as an integral part of individualising therapy.
Recruitment of new participants to the study will be halted
temporarily on the advice of the data monitoring and eth-
ics committee if any of the following are noted: a patient
death attributable to treatment or an unacceptable inci-
dence of severe adverse events attributable to treatment (if
occurring in >10% of patients). In both these instances,
the trial will undergo urgent review by the data monitor-
ing and ethics committee and the trial steering committee.
The investigator has the right to withdraw patients
from treatment with the study drug in the event of inter-
current illnesses, adverse events, severe adverse events,
suspected unexpected serious adverse reactions, protocol
violations, cure, administrative reasons or other reasons. It
is understood by all concerned that an excessive rate of
withdrawals can render the study uninterpretable and
unnecessary withdrawal of patients should be avoided.
Should a patient decide to withdraw from the study, all ef-
forts will be made to report the reason for withdrawal as
thoroughly as possible. Should a patient withdraw from
treatment with the study drug only, efforts will be made to
obtain follow-up data, with the permission of the patient.
Participants who wish to withdraw from treatment will
be asked to confirm whether they are still willing to pro-
vide study-specific data and samples for scientific labora-
tory analysis according to the trial protocol.
Expected duration of trial
The trial is expected to recruit for 3 years. We estimated
that the minimum number of individuals in each of groups
C and D still HLA Ab– at the primary end point should be
627 (see Figure 1). The recruitment target is to randomise
950 patients to each of these groups. This allows for the
predicted dropout rate and the rate of antibody conversion
with a margin of error. Patients will be followed up for a
period of 3 years post-recruitment, except for patients in
groups C and D who become Ab + during the initial 3
years of follow-up, who will transfer to the relevant Ab +
group and be followed up for a further 3 years from the
date of transfer. Therefore, the maximum amount of time
that any single patient can remain in the study is 6 years.
Communication of the need for an extended follow-up will
be made at the final HLA screening round at month 32,
after the primary outcome data have been collected, to
avoid unblinding the HLA status in the blinded care arm.
Trial procedures
Synopsis
A structured screening programme for IgG HLA Ab is
proposed in patients who provide consent. Results ob-
tained will initially be blinded to the transplant clinicians
and patients. Patients will be randomised through the
King’s Clinical Trials Unit and stratified: (1) DSA+, non-
DSA + or HLA Ab–, (2) by current immunosuppression
(tac alone, MMF alone, both tac and MMF, or neither
tac nor MMF) and (3) recruiting study site. Patients in
groups A1, A2 and C (see flow diagram in Figure 1) will
remain blinded to the results of their screening (as will
their clinicians), whereas those in B1, B2 and D will learn
whether they are HLA Ab + or Ab–. All recruits will
undergo a final test for HLA Ab status as they reach the
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end of the study. The optimised treatment protocol for
patients in the two groups with HLA Ab (B1 and B2) is
outlined above. Patients in all groups will have blood pres-
sure controlled and total cholesterol lowered, according to
local unit guidelines.
First visit
Post consent, patients who have not been screened for
HIV or hepatitis B/C within the last 5 years will undergo
additional screening tests for these viruses. Female pa-
tients who report they may be pregnant will have a blood
test for beta-Human Chorionic Gonadotrophin levels.
Once eligibility criteria have been met, the following base-
line data will be recorded at recruitment:
 Weight
 Blood pressure
 Sex
 Ethnicity
 Age
 Date of birth
 HLA type
 HLA type of donor kidney (if known)
 Any significant past medical history, including history
of diabetes mellitus, cause of renal failure, details of
previous transplants and cause of graft loss, evidence
of sensitisation pre-transplantation (panel reactive
antibody and antibody specificities if known)
 Medication including doses
 PCR of urine sample
All patients will then have blood taken for;
 Baseline clinical parameters: full blood count
(minimum haemoglobin, white cell count, platelets);
biochemical series (creatinine, Na+, K+, bicarbonate,
calcium, C-reactive protein, lipid profile, glucose);
MDRD eGFR on latest creatinine; current calcine-
urin inhibitor 12-hour trough levels (as appropriate);
total immunoglobulin levels
 Scientific analyses: 50 to 60 mL blood for separation
of peripheral blood mononuclear cells (PBMC) and
20 mL for serum storage
 Analysis of HLA Ab status (10 mL clotted blood), as
described above, which will allow randomisation to
proceed
All patients will be asked to complete questionnaires
to assess attitudes to risk and adherence.
Subsequent visits
The optimised treatment protocol will be introduced
within the first 3 months in those HLA Ab + patients al-
located to this group. Recruits will be seen up to every
two weeks during this period (a maximum of six extra
clinic appointments are envisaged), though they should
be on a maintenance dose of prednisolone 7 weeks after
initiating optimisation. During this period they will have
full blood count (as above), creatinine, Na+, K+, glucose,
calcineurin inhibitor trough levels and blood pressure
monitored according to the trial protocol. Once stabi-
lised, they will be seen at least every 4 months in the
transplant clinic. Patients allocated to all other groups
will be seen at least every 4 months in the transplant
clinic for formal study assessments. Patients may be seen
at other times during this period, according to clinical
need, but study assessments should be done within the
time parameters established in the protocol.
Once every 4 months the following will be recorded:
 Weight
 Blood pressure
 Full blood count (minimum haemoglobin, white cell
count, platelets)
 Biochemical series (creatinine, Na+, K+, bicarbonate,
calcium, C-reactive protein, glucose)
 MDRD eGFR on latest creatinine
 Calcineurin inhibitor trough levels
 PCR of urine sample
 Total immunoglobulin levels
 Episodes of infection, malignancy or new DM
 Episodes considered to be adverse events
Every 12 months, each patient’s lipid profile will be
measured.
For all patients with HLA Ab, and a small cohort of
patients without, separate blood samples will be taken
for non-routine scientific analyses as above. Steps will be
taken to ensure this sampling does not break the blind-
ing of group allocations. Once every 8 months, HLA
Ab– patients will undergo further screening for HLA Ab
(see above). At the end of the study, all patients will
undergo a final test for HLA Ab status.
In recruits with living donors (known to them), the liv-
ing donors will be invited to participate either by the re-
cruit or directly by the study team, following consent from
the recruit to inform donors of their participation in the
study. Donors will attend the clinic at their convenience,
where consent will be taken and blood (60 mL) taken for
separation of PBMC, which will be stored in the research
laboratory, identified only as from the donor of a particu-
lar study recruit. Donors may be asked to donate another
aliquot of blood at another time within the next 3 years.
Laboratory tests
Human leukocyte antigen antibody analysis
Serum prepared from 10 mL of blood will be used in the
commercially available LABScreen tests (One Lambda,
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Canoga Park, CA), containing fluorescently tagged beads
coated with purified HLA antigens. All participating cen-
tres have Luminex equipment (Luminex Corp, Austin,
Texas) for analysis of these tests and the skills to process
samples and interpret results. Therefore, the tests will be
performed in each of the centres. A sequential analysis of
samples is planned, first to identify those with HLA Ab,
using mixed class I and class II Ab screening beads coated
with multiple different types of HLA. The manufacturer’s
definition of positive and negative tests will be used when
interpreting the results. In those patients with positive re-
sults, the specificity of the HLA Ab will be determined by
SAB, coated with single HLA class I or class II antigens.
As before, when interpreting the results, the manufac-
turer’s definition of positive and negative tests will be
used. Any patient with a positive test for HLA Ab identi-
fied by SAB will be regarded as HLA Ab + for the trial if
the mean fluorescence intensity (MFI) is ≥2,000. If the
HLA Ab are directed against a mismatched donor HLA
antigen, the patient will be assigned as DSA+. The num-
ber of DSA with MFI ≥ 2,000 will be used to define the Ab
‘burden’ of an individual. In the final analysis, correlations
between HLA Ab burden and outcomes will be sought.
Patients with SAB positivity that is difficult to label as
DSA + or non-DSA + (because of insufficient data on
donor mismatches, for instance), will be regarded as being
non-DSA+. Patients with a positive reaction on screening
but lacking reactivity with the SAB at the level described
will be considered negative. Excess serum will be stored.
The same screening will be undertaken for HLA Ab– pa-
tients every 8 months, with the samples taken at a routine
clinic appointment.
Routine biochemical, haematological and calcineurin
inhibitor trough analysis
These will be performed by the local clinical laboratories
and the results recorded as above.
Scientific laboratory analysis
A laboratory analysis will be performed at recruitment
for all patients and then every 4 months on patients with
HLA Ab and a small cohort of patients who are HLA
Ab–, chosen randomly at randomisation. Then, 60 to 80
mL blood will be taken and 20 mL for serum. The sam-
ples will be sent to the research laboratory of the chief
investigator where the blood will be separated into
PBMC and CD34+ cells. DNA and RNA will be ex-
tracted from a small number of cells and stored. All
other cells will be stored in aliquots in liquid nitrogen
until thawed for analysis. Serum samples will be stored
at −80°C until thawed for analysis. The same process for
preparing PBMC will be used for the samples from
donors.
Patients will also consent to analysis, for research
purposes, of any stored serum, blood or tissue (such as
transplant biopsies). This will apply for all existing and
future samples taken for clinical reasons. In the case of
future transplant biopsies, the patients will be asked to
consent to having an extra core taken for transcriptome
analysis. Subject to available funding, this will be stored
in an appropriate medium and transported to the chief
investigator’s laboratory for storage.
Procedures for assessing efficacy parameters
Graft failure is defined as the return to long-term dialysis
or re-transplantation. This will be measured from the date
of recruitment and will be reported for failure due to any
cause. The date of restarting dialysis or re-transplantation
will be recorded on the Case Report Form.
Deteriorating renal function will be determined by lin-
ear regression analysis of the serial MDRD eGFRs from
the point of recruitment (like that used by Dudley et al.
[14]). Deterioration is defined as a negative slope. To be
valid, the linear regression should yield an adjusted r2 ≥
0.35 and have P ≤ 0.05 for the slope value. Stable renal
function will be defined as serial MDRD eGFRs that are
not significantly different from the horizontal baseline
(that is, P > 0.05 on linear regression analysis). An im-
provement in renal function will be defined as a change
in the slope so that it becomes positive. Serum creatin-
ine levels and MDRD eGFR for the 12 months preceding
recruitment and for the whole time patients are on the
trial will be recorded on the CRF.
Proteinuria is defined by the PCR of a urine sample
and is significant if >50. The PCR will be recorded on
the CRF.
Acute rejection is defined by a combination of: (a) an
acute rise in serum creatinine prompting a renal biopsy
and (b) any pathology on the biopsy that meets the cri-
teria for acute rejection, according to the latest BANFF
criteria. The number of biopsies and the appropriate bi-
opsy reports will be recorded on the CRF.
A full economic evaluation will adopt a National Health
Service (NHS) perspective. The 3-year outcomes are the
rates of: (1) graft failure, (2) patient survival, (3) graft dys-
function (see definition above), (4) acute rejection and (5)
culture-positive infection, malignancy or diabetes, together
with (6) EQ-5D, which is a patient-specific quality-adjusted
life years (QALY) measurement. Cost-effectiveness will use
(1) to (5) where (1) is the primary and the others are sec-
ondary outcomes. Cost-utility will be measured using (6)
(the EQ-5D questionnaire). The net benefit per patient will
be calculated by multiplying QALY by the assumed max-
imum willingness-to-pay for QALY (£20,000 per QALY)
and subtracting the costs. The costs of all interventions will
be obtained from Guy’s or estimated by identifying relevant
categories of resource utilisation or measuring the volume
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of each category and multiplying by the average NHS re-
source costs [15] (and using British National Formulary
and NHS reference lists). The costs of an intervention in-
clude the cost of screening beads and enhanced drug costs.
Participants’ reporting of adherence will be assessed
using the Medicines Adherence Report Scale (MARS)
[16,17], a valid and reliable scale that has been previ-
ously used to assess adherence in renal transplant recipi-
ents [18,19]. Self-report measures have the advantage of
being inexpensive and non-intrusive. However, it is
known that self-reporting underestimates the true extent
of non-adherence because of inherent self-presentational
and recall biases. Self-presentational bias occurs when re-
spondents may be reluctant to admit to non-adherence
because they perceive a social contract where the expect-
ation is one of high adherence. MARS takes steps to di-
minish this bias by sanctioning and normalising reports of
non-adherence. However, this does not totally remove the
effect of self-presentational and recall biases that are
inherent in all self-report measures. For this reason we
will apply a combined approach to adherence assessment,
where an initial categorisation of patients into high vs low
on the basis of self-reporting is revised based on calcine-
urin inhibitor blood monitoring (carried out in routine
management for patients prescribed tacrolimus or ciclos-
porin) and tablet counts (conducted for a sample of par-
ticipants). In this approach, reports of low adherence are
accepted as self-presentational biases that act in the op-
posite direction (reports of low adherence are more reli-
able than reports of high adherence [20,21]). Patients who
report high adherence are reclassified to low adherence on
the basis of calcineurin inhibitor trough results (for ex-
ample, if levels are undetectable then the participant is as-
sumed to be non-adherent) or tablet counts (for example,
if there is a greater than 20% discrepancy between the ac-
tual and expected tablet count then the participant is re-
classified as non-adherent).
To explore the potential antecedents to participants’
adherence behaviours, they will be also be asked to
complete specially adapted versions of questionnaires re-
lating to treatment intrusiveness, symptoms associated
with immunosuppressants, beliefs about medicines [22],
satisfaction with information about their medicines [23]
and whether they are feeling anxious and/or depressed
[24]. Questionnaires will be used to qualify perceptions
of personal risk [25]. On the basis of survey responses, a
small number of participants will be purposively selected
(for example, those with positive and negative attitudes,
and high and low adherers) for qualitative interview to
explore their perception of risk and adherence behav-
iours in more depth.
All patients taking part in the trial will be asked to
complete all or some of the questionnaires at specified
times. Questionnaires will be administered electronically.
Respondents will complete a survey online whilst in a
clinic, using an iPad or equivalent tablet device desig-
nated solely for this trial. Completed survey responses
are stored on Qualtrics secure servers and can only be
accessed using a login and password. Nothing will be re-
corded on the main trial CRFs.
The questionnaires will be piloted with the first few
participants recruited to the Guy’s site. These respon-
dents will be asked to undergo cognitive interviewing
whilst completing the survey, a technique used to ensure
the validity of questionnaire items [26]. On the basis of
this pilot, the questionnaire items may undergo minor
modification. The ease of utility of the online survey and
tablet device will also be evaluated during the pilot.
Ethical approval
The OuTSMART trial has been approved by the National
Research Ethics Service Committee London, Hampstead,
(REC number 12/LO/1759 on 14 January 2013) and by
the MHRA (EudraCT number 2012-004308-36 on 24
December 2012).
Discussion
Research by others working in this area has mostly fo-
cussed on how to treat established CR. All reports con-
sider small numbers of patients. Theruvath et al. reported
12-month stabilisation of kidney function in ¾ patients
with kidney dysfunction due to CR associated with HLA
Ab after transfer onto tac and MMF and a short course of
prednisolone [27]. In addition, several studies have re-
ported successful stabilisation of CR using B cell depletion
therapy [28-30], further supporting the hypothesis that
targeting underlying cellular responses, rather than HLA
Ab, is a rational approach to treatment for these patients.
Several other strands of evidence support the use of an
optimised tac and MMF regime to prevent progression
of CR. First, both MMF [31] and tac [32] are better at
suppressing acute rejection than alternative agents and
the combination of the two agents achieves better out-
comes at 1 and 2 years compared to alternative regimes
[33,34]. Second, regimes containing MMF are associated
with a lower prevalence of HLA Ab [35] and MMF
specifically reduces the development of HLA Ab during
episodes of acute rejection [36]. Third, although these
benefits have not always fed through to improvements
in graft survival rates, one recent landmark study did
show improved graft survival for a combination of tac
and MMF [37]. For tac, enhanced graft survival also
emerged during a systematic Cochrane review compar-
ing tac with ciclosporin [34]. For MMF, a retrospective
analysis of United States registry data revealed an associ-
ation with significantly lower rates of premature allograft
failure [38]. Finally, some studies have shown that con-
version from ciclosporin to tac is beneficial for patients
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with deteriorating graft function [39], and that introduc-
tion of MMF has a similar effect [40]. Although other
studies have reported contradictory results [41], much of
this literature is difficult to interpret because many stud-
ies do not distinguish between CR and other causes of
chronic graft dysfunction [42].
In addition to tac and MMF, we propose to use a short
course of moderate-dose prednisolone followed by low
dose steroid maintenance in this trial. There is no direct
evidence from the transplant literature to support this
intervention, but a similar treatment course is standard
therapy in many situations where quick and effective sup-
pression of immune responses is required, for example in
acute asthma and in many types of autoimmune diseases.
In summary, this trial will identify a group of patients
at high risk of premature transplant failure. Therapy will
be optimised for these at-risk patients, many of whom
will be identified before they have started to deteriorate
clinically. As described above, the natural history of un-
treated CR is of progressive loss of function, usually at a
predictable rate, leading eventually to complete loss of
graft function. Depending on the initial creatinine level,
the time to graft loss will be variable, but graft loss rarely
occurs without this period of progressive loss of function.
Lachmann et al. [8] reported a constant rate of graft loss
from the start of their study, so we expect that the rate of
graft loss in our study will be constant in the standard care
group. We predict that optimised immunotherapy will
change the natural history of the condition, and lead to
stabilisation of function in a significant proportion (50%)
of those with HLA Ab. This will be visible in our analyses
of the secondary end points. Hopefully the treatment
will prevent the predicted graft loss in the first 3 years
for this group and thus impact on the primary end point
of the study.
Trial status
At the time of submission, the study has a planned re-
cruitment start date of 27 August 2013.
Endnotes
aIn the transplantation literature, this problem is called
‘late’ allograft failure, in which ‘late’ refers to the lifespan
of the transplanted organ. We have changed the term to
shift the emphasis to the recipient.
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